EU Approves Bayer's Heart-Failure Drug
21 Juli 2021 - 01:15PM
Dow Jones News
By Cecilia Butini
Bayer AG said Wednesday that its heart-failure treatment,
Verquvo, was granted marketing authorization in the European
Union.
The German conglomerate said the treatment, also known as
vericiguat, is for patients with chronic heart failure who have
suffered a worsening in their condition.
Verquvo is already approved in the U.S. and Japan. Marketing
authorization for the drug has been submitted in China and other
countries world-wide, Bayer said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
July 21, 2021 07:13 ET (11:13 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Bayer (TG:BAYN)
Historical Stock Chart
Von Mär 2023 bis Mär 2024